Clinical trial
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
NCT00234065 · Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00234065 |
|---|---|
| Title | Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Official title | Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin |
| Lead sponsor | Otsuka Pharmaceutical Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cerebral Infarction |
| Intervention type | Drug |
| Interventions | Cilostazol, Aspirin |
| Enrollment | 2,800 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 6, 2005 |
| Last update posted | Jun 10, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: